Custom-Made immune cells tested as new weapon against tough cancers
NCT ID NCT07207681
Summary
This is a first-in-human study to test the safety and early signs of effectiveness of a new, personalized gene therapy called KXV01 for people with advanced solid tumors. The therapy involves collecting a patient's own tumor-fighting immune cells, modifying them with a virus to better target their cancer, and then reinfusing them. The study will enroll about 30 adults whose cancer has progressed despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Hospital of Jilin University
Changchun, Jilin, 130013, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.